SITE003-0301

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-02-24

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-03 (study day 56); relationship: N

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 147); relationship: Y

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 158); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 168); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-30 (study day 206); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 231); relationship: not assessed

severe serious assessed

Grade 3 Nausea — outcome: UNKNOWN; onset 2023-10-30 (study day 236); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.